EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

Karen-Lise G Spindler, Niels Pallisgaard, Jan Lindebjerg, Sanne K Frifeldt, Anders Jakobsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

ABSTRACT:
OriginalsprogEngelsk
TidsskriftB M C Cancer
Vol/bind11
Sider (fra-til)107
ISSN1471-2407
DOI
StatusUdgivet - 1. jan. 2011

Fingeraftryk

irinotecan
Colorectal Neoplasms
Cetuximab

Citer dette

@article{d107d8b0257747c88753f6db1808910f,
title = "EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer",
abstract = "ABSTRACT:",
author = "Spindler, {Karen-Lise G} and Niels Pallisgaard and Jan Lindebjerg and Frifeldt, {Sanne K} and Anders Jakobsen",
year = "2011",
month = "1",
day = "1",
doi = "10.1186/1471-2407-11-107",
language = "English",
volume = "11",
pages = "107",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. / Spindler, Karen-Lise G; Pallisgaard, Niels; Lindebjerg, Jan; Frifeldt, Sanne K; Jakobsen, Anders.

I: B M C Cancer, Bind 11, 01.01.2011, s. 107.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

AU - Spindler, Karen-Lise G

AU - Pallisgaard, Niels

AU - Lindebjerg, Jan

AU - Frifeldt, Sanne K

AU - Jakobsen, Anders

PY - 2011/1/1

Y1 - 2011/1/1

N2 - ABSTRACT:

AB - ABSTRACT:

U2 - 10.1186/1471-2407-11-107

DO - 10.1186/1471-2407-11-107

M3 - Journal article

VL - 11

SP - 107

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

ER -